Squarepoint’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$30.3M Sell
32,900
-40,500
-55% -$41.1M 0.04% 508
2025
Q4
$78.9M Sell
73,400
-2,400
-3% -$2.29M 0.08% 263
2025
Q3
$57.8M Sell
75,800
-56,600
-43% -$42.1M 0.06% 368
2025
Q2
$103M Sell
132,400
-11,400
-8% -$8.86M 0.11% 200
2025
Q1
$119M Sell
143,800
-91,500
-39% -$76.1M 0.14% 129
2024
Q4
$182M Buy
235,300
+161,100
+217% +$133M 0.18% 83
2024
Q3
$65.7M Buy
74,200
+47,300
+176% +$42.5M 0.1% 180
2024
Q2
$24.4M Sell
26,900
-69,400
-72% -$55.5M 0.04% 493
2024
Q1
$74.9M Buy
96,300
+6,300
+7% +$4.48M 0.13% 150
2023
Q4
$52.5M Sell
90,000
-41,400
-32% -$24.2M 0.1% 213
2023
Q3
$70.6M Buy
131,400
+94,900
+260% +$48.9M 0.17% 102
2023
Q2
$17.1M Buy
36,500
+35,300
+2,942% +$14.8M 0.05% 445
2023
Q1
$412K Sell
1,200
-5,600
-82% -$1.89M ﹤0.01% 2405
2022
Q4
$2.49M Sell
6,800
-101,600
-94% -$36M 0.01% 1239
2022
Q3
$35.1M Buy
108,400
+91,800
+553% +$29.1M 0.18% 109
2022
Q2
$5.38M Buy
16,600
+7,100
+75% +$2.13M 0.03% 641
2022
Q1
$2.72M Sell
9,500
-41,600
-81% -$10.7M 0.01% 973
2021
Q4
$14.1M Sell
51,100
-600
-1% -$152K 0.04% 411
2021
Q3
$11.9M Buy
51,700
+500
+1% +$123K 0.03% 442
2021
Q2
$11.8M Buy
51,200
+47,200
+1,180% +$9.48M 0.04% 406
2021
Q1
$747K Buy
4,000
+2,700
+208% +$528K ﹤0.01% 1735
2020
Q4
$219K Sell
1,300
-500
-28% -$74.7K ﹤0.01% 2447
2020
Q3
$266K Buy
1,800
+500
+38% +$77.4K ﹤0.01% 1892
2020
Q2
$213K Buy
+1,300
New +$200K ﹤0.01% 1795
2020
Q1
Sell
-4,100
Closed -$539K 2225
2019
Q4
$539K Buy
4,100
+2,100
+105% +$243K ﹤0.01% 1730
2019
Q3
$224K Buy
+2,000
New +$223K ﹤0.01% 2035

Other funds holding LLY

Squarepoint's LLY Position: Q1 2026 in Review

Squarepoint increased its Eli Lilly (LLY) stake by 38% in Q1 2026, buying an estimated $81.6M and bringing the position to 290,181 shares worth $267M. The position accounts for 0.31% of the portfolio, ranked #35.

Squarepoint first reported a position in LLY in Q1 2015 and has held it in 33 quarters since. The position peaked at $346M in Q3 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Squarepoint held 290,181 shares of Eli Lilly worth $267M as of Q1 2026.
  • Squarepoint bought 80,448 Eli Lilly shares in Q1 2026, an estimated $81.6M.
  • Eli Lilly made up 0.31% of Squarepoint's portfolio in Q1 2026, its #35 holding.
  • Squarepoint first reported a position in Eli Lilly in Q1 2015 and has held it in 33 quarters since.
  • Squarepoint's Eli Lilly position peaked at $346M in Q3 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.